Literature DB >> 35844393

Bacteriophage therapy as an alternative biocontrol against emerging multidrug resistant E. coli in broilers.

Samah Eid1, Hala M N Tolba2, Rehab I Hamed3, Nayera M Al-Atfeehy1.   

Abstract

Avian pathogenic Escherichia coli (APEC) is considered a severe issue to both poultry business and health of the general public. In that context, 50 samples from 250 diseased broiler chickens in 10 chicken farms were employed to Escherichia coli isolation. Microbiological techniques were employed to detect isolates of E. coli from 250 diseased broiler chickens which were examined by antimicrobial susceptibility profiles against 11 antimicrobial agents using disc diffusion technique as well as their biofilm forming capacity were detected. In addition to, study the isolation and purification of phages based on spot technique to verify that lytic phages are present in E. coli isolates and plaque assay for titration of bacteriophages. In the present research, we also looked at the ability of bacteriophages to inhibit and dissolve previously formed biofilms by E. coli O78 isolate. Moreover, experimental testing of E. coli O78 bacteriophages for colibacillosis prevention and control in one day old broiler chicks were done. The obtained results showed that twenty-six E. coli isolates out of 50 examined samples were isolated (10.4%). The most prevalent serotypes were O78, O121:H7, O146:H2, O124, O113:H4, O112:H2, O1:H7, O55:H7, O2:H6, O91:H21, O26:H11. Antibiogram results demonstrated the resistance of E. coli isolates with high percentage 100% were against, Ampicillin, Amoxicillin and Tetracycline. Biofilm quantification analysis showed that 24/26 (92.3%) isolates were considered biofilm producer isolates. The characterization and the lytic activity of bacteriophage were performed based on Transmission electron microscopy and showed the greatest lytic activity against the evaluated host strains with effective activity at concentration of 107 at 24 h and strong significant reduction of the established E. coli O 78 biofilm within 12 h. The result of experimental infection showed that the performance indicators of phage in treated and challenged group showed high significant increase in body weight, weight gain and improved FCR than infected -antibiotic treated and infected bacteriophage and antibiotic treated. Total viable cell counts of E. coli in the lungs of birds revealed that there is highly significant difference between the six groups count results. We concluded that phage therapy found to be an attractive option to prevent and control multidrug resistant colibacillosis in broilers.
© 2022 The Authors.

Entities:  

Keywords:  APEC; Antibiotic resistance; Bacteriophage; Biofilm; Escherichia coli; Phage therapy

Year:  2022        PMID: 35844393      PMCID: PMC9280247          DOI: 10.1016/j.sjbs.2022.02.015

Source DB:  PubMed          Journal:  Saudi J Biol Sci        ISSN: 2213-7106            Impact factor:   4.052


  47 in total

1.  Prevention of Escherichia coli infection in broiler chickens with a bacteriophage aerosol spray.

Authors:  W E Huff; G R Huff; N C Rath; J M Balog; A M Donoghue
Journal:  Poult Sci       Date:  2002-10       Impact factor: 3.352

2.  Evaluation of the efficiency of using Salmonella Kentucky and Escherichia coli O119 bacteriophages in the treatment and prevention of salmonellosis and colibacillosis in broiler chickens.

Authors:  Hend K Sorour; Ahmed F Gaber; Reham A Hosny
Journal:  Lett Appl Microbiol       Date:  2020-07-06       Impact factor: 2.858

3.  Bacteriophage Esc-A is an efficient therapy for Escherichia coli 3-1 caused diarrhea in chickens.

Authors:  Huijun Xie; Xuliang Zhuang; Jian Kong; Guirong Ma; Hongxun Zhang
Journal:  J Gen Appl Microbiol       Date:  2005-06       Impact factor: 1.452

Review 4.  Antimicrobial resistance: a microbial risk assessment perspective.

Authors:  Emma L Snary; Louise A Kelly; Helen C Davison; Christopher J Teale; Marion Wooldridge
Journal:  J Antimicrob Chemother       Date:  2004-04-21       Impact factor: 5.790

5.  Detection of virulence-associated genes in pathogenic and commensal avian Escherichia coli isolates.

Authors:  A C Paixão; A C Ferreira; M Fontes; P Themudo; T Albuquerque; M C Soares; M Fevereiro; L Martins; M I Corrêa de Sá
Journal:  Poult Sci       Date:  2016-03-14       Impact factor: 3.352

6.  Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase.

Authors:  Kevin A Hughes; Ian W Sutherland; Martin V Jones
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

Review 7.  Advances in vaccination against avian pathogenic Escherichia coli respiratory disease: potentials and limitations.

Authors:  Haitham Ghunaim; Marwan Abdelhamid Abu-Madi; Subhashinie Kariyawasam
Journal:  Vet Microbiol       Date:  2014-05-05       Impact factor: 3.293

8.  Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation.

Authors:  Iara Rossi Gonçalves; Raquel Cristina Cavalcanti Dantas; Melina Lorraine Ferreira; Deivid William da Fonseca Batistão; Paulo Pinto Gontijo-Filho; Rosineide Marques Ribas
Journal:  Braz J Microbiol       Date:  2016-11-26       Impact factor: 2.476

9.  Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms.

Authors:  Lindsey B Coulter; Robert J C McLean; Rodney E Rohde; Gary M Aron
Journal:  Viruses       Date:  2014-10-03       Impact factor: 5.048

10.  Three New Escherichia coli Phages from the Human Gut Show Promising Potential for Phage Therapy.

Authors:  Marion Dalmasso; Ronan Strain; Horst Neve; Charles M A P Franz; Fabien J Cousin; R Paul Ross; Colin Hill
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

View more
  1 in total

Review 1.  From Farm to Fork: Streptococcus suis as a Model for the Development of Novel Phage-Based Biocontrol Agents.

Authors:  Emmanuel Kuffour Osei; Jennifer Mahony; John G Kenny
Journal:  Viruses       Date:  2022-09-09       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.